meta
|
Preg
- medecines during pregnancy KB
Search
Triptans
Overall results
Study description
Excluded studies
Table
Graphic
auto
during pregnancy (anytime or not specified)
1st trimester
2nd trimester
3rd trimester
2nd and/or 3rd trimester
throughout pregnancy
early pregnancy
days before delivery
late pregnancy
preconception-only
periconceptional
preconceptional for kinetic reason
at least 1st trimester
3 months (or more) before pregnancy or during pregnancy
1st and 2nd trimester
3 months or more before pregnancy or1st trimester
Whatever the period exposition
individual studies
Outcome
TE
95% CI
n cases
n exposed
k
Pub. bias
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)
Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 Källén (control unexposed, disease free), 2011 Nezvalová-Henriksen (Control unexposed, sick), 2013 Spielmann (Control unexposed, disease free), 2017
4
0.99
[
0.85
; 1.15]
57,146
4,397
not evaluable
Major congenital malformations
Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 Källén (control unexposed, disease free), 2011 Nezvalová-Henriksen (Control unexposed, sick), 2013 Spielmann (Control unexposed, disease free), 2017
4
0.97
[
0.81
; 1.17]
39,057
4,392
not evaluable
Congenital heart defects
Källén (control unexposed, disease free), 2011 De Jonge - Sumatriptan, 2013
2
1.32
[
0.61
; 2.88]
13,707
2,839
not evaluable
Chromosomal abnormalities
Spielmann (Control unexposed, disease free), 2017
1
1.18
[
0.44
; 3.17]
25
325
not evaluable
Limb defects
De Jonge - Sumatriptan, 2013
1
1.37
[
0.08
; 22.33]
184
58
not evaluable
Minor congenital malformations
O'Quinn - Sumatriptan, 1999 Spielmann (Control unexposed, disease free), 2017
2
0.68
[
0.06
; 8.05]
46
387
not evaluable
Nervous system anomalies
De Jonge - Sumatriptan, 2013
1
1.22
[
0.07
; 19.75]
208
58
not evaluable
Oro-facial clefts
De Jonge - Sumatriptan, 2013
1
0.86
[
0.05
; 13.97]
294
58
not evaluable
Digestive system anomalies
De Jonge - Sumatriptan, 2013
1
0.70
[
0.04
; 11.34]
362
58
not evaluable
Eye defects
0
-
-
-
-
-
Genital anomalies
De Jonge - Sumatriptan, 2013
1
0.81
[
0.05
; 13.08]
314
58
not evaluable
Urinary malformations
0
-
-
-
-
-
Abdominal wall defects
0
-
-
-
-
-
Cardiac septal defects
Källén (control unexposed, disease free), 2011
1
1.08
[
0.67
; 1.74]
6,792
2,777
not evaluable
Ear, face and neck anomalies
0
-
-
-
-
-
Gastroschisis
Werler, 2009
1
0.80
[
0.10
; 6.38]
514
9
not evaluable
Other anomalies/syndromes (non chromosomal)
0
-
-
-
-
-
Respiratory system anomalies
0
-
-
-
-
-
Growth parameters and prematurity
Preterm (< 37 weeks)
Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 Olesen - Sumatriptan (Control unexposed, sick), 2000 Källén (control unexposed, disease free), 2011 Bérard, 2012 Nezvalová-Henriksen (Control unexposed, sick), 2013 Wood 2016a (Control exposed only before pregnancy), 2016 Spielmann (Control unexposed, disease free), 2017
7
1.03
[
0.71
; 1.48]
4,470
2,480
not evaluable
Low birth weight (< 2500g)
Olesen - Sumatriptan (Control unexposed, sick), 2000 Kallen - Sumatriptan, 2001 Bérard, 2012 Nezvalová-Henriksen (Control unexposed, sick), 2013 Wood 2016a (Control exposed only before pregnancy), 2016
5
0.92
[
0.71
; 1.19]
3,578
2,692
not evaluable
Small for gestational age (weight)
Nezvalová-Henriksen (Control unexposed, sick), 2013 Wood 2016a (Control exposed only before pregnancy), 2016
2
1.08
[
0.85
; 1.38]
299
1,861
not evaluable
Very low birth weight (< 1500g)
Kallen - Sumatriptan, 2001
1
0.73
[
0.10
; 5.40]
-
658
not evaluable
Maternal consequences
Preeclampsia
Nezvalová-Henriksen (Control unexposed, sick), 2013 Wood 2016a (Control exposed only before pregnancy), 2016 Spielmann (Control unexposed, disease free), 2017
3
1.25
[
0.73
; 2.14]
275
2,183
not evaluable
Abruptio placentae (retroplacental hematoma)
Spielmann (Control unexposed, disease free), 2017
1
2.80
[
0.60
; 13.08]
9
432
not evaluable
Caesarean
Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998
1
1.53
[
0.74
; 3.16]
38
80
not evaluable
Gestational diabetes
Nezvalová-Henriksen (Control unexposed, sick), 2013
1
0.75
[
0.33
; 1.67]
24
1,465
not evaluable
Postpartum hemorrhage
Nezvalová-Henriksen (Control unexposed, sick), 2013
1
0.69
[
0.44
; 1.09]
219
185
not evaluable
Neonatal disorders
Low Apgar score (< 7) (at 5 min)
Wood 2016a (Control exposed only before pregnancy), 2016
1
1.52
[
0.52
; 4.41]
14
396
not evaluable
Neonatal medical care
Nezvalová-Henriksen (Control unexposed, sick), 2013
1
0.77
[
0.45
; 1.33]
136
185
not evaluable
Intrauterine deaths
Early intrauterine death (< 22 weeks)
Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 O'Quinn - Sumatriptan, 1999 Bérard, 2012 Spielmann (Control unexposed, disease free), 2017
4
1.64
[
0.94
; 2.86]
5,012
686
not evaluable
Elective/induced termination of pregnancy
O'Quinn - Sumatriptan, 1999 Spielmann (Control unexposed, disease free), 2017
2
1.11
[
0.42
; 2.98]
108
508
not evaluable
Late intrauterine deaths (> 22 weeks)
O'Quinn - Sumatriptan, 1999 Spielmann (Control unexposed, disease free), 2017
2
0.65
[
0.11
; 3.86]
7
508
not evaluable
Ectopic pregnancy
O'Quinn - Sumatriptan, 1999
1
1.21
[
0.07
; 19.73]
2
76
not evaluable
Intrauterine deaths (as a whole or unspecified)
Nezvalová-Henriksen (Control unexposed, disease free), 2013
1
1.01
[
0.56
; 1.83]
-
-
not evaluable
Perinatal death
Kallen - Sumatriptan, 2001
1
1.23
[
0.40
; 3.80]
-
658
not evaluable
0.0
50.0
1.0
